Literature DB >> 19184636

Familial parathyroid tumors: diagnosis and management.

Peter Stålberg1, Tobias Carling.   

Abstract

BACKGROUND: The management of hyperparathyroidism (HPT) in the familial setting is complex. Due to the rarity of familial HPT and its different presentation within and between the familial syndromes and individual kindreds, treatment recommendations based on high levels of evidence cannot be made. However, based on the molecular genetic studies and case series from institutions with significant experience, important management principles (grade C recommendations) have been developed.
METHODS: We conducted a systematic review of the literature using evidence-based criteria.
RESULTS: Issue 1: initial operation in multiple endocrine neoplasia type 1 (MEN1), a grade C recommendation can be made for subtotal parathyroidectomy. Issue 2: initial surgery in MEN 2A, a grade C recommendation can be made for excision of enlarged glands only. Issue 3: surgery in familial isolated HPT and HPT-jaw tumor (HPT-JT) syndrome may be treated with parathyroidectomy that is subtotal or less, although the risk of parathyroid cancer in HPT-JT requires attention (no grade of recommendation). Issue 4: parathyroid surgery in familial HPT syndromes in the setting of underlying mutations in the calcium receptor (CASR) gene involves subtotal parathyroidectomy (no grade of recommendation). Issue 5: the use of intraoperative PTH measurements in familial HPT may guide the extent of parathyroid resection (no grade of recommendation).
CONCLUSIONS: The goals of parathyroidectomy in familial HPT are to achieve and maintain normocalcemia for the longest time possible, avoid both iatrogenic hypocalcemia and operative complications, and facilitate future surgery for recurrent disease.

Entities:  

Mesh:

Year:  2009        PMID: 19184636     DOI: 10.1007/s00268-009-9924-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  64 in total

1.  Impact of intraoperative parathyroid hormone monitoring on the prediction of multiglandular parathyroid disease.

Authors:  Thomas Clerici; Michael Brandle; Jochen Lange; Gerard M Doherty; Paul G Gauger
Journal:  World J Surg       Date:  2004-01-08       Impact factor: 3.352

2.  Focused approach to parathyroidectomy.

Authors:  Tobias Carling; Robert Udelsman
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

Review 3.  Role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism.

Authors:  H Richard Alexander; Clara C Chen; Thomas Shawker; Peter Choyke; Teresa J Chan; Richard Chang; Stephen J Marx
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

4.  Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential?

Authors:  C Dotzenrath; K Cupisti; P E Goretzki; Q Yang; D Simon; C Ohmann; H D Röher
Journal:  Eur J Surg       Date:  2001-03

5.  Neonatal severe hyperparathyroidism, secondary hyperparathyroidism, and familial hypocalciuric hypercalcemia: multiple different phenotypes associated with an inactivating Alu insertion mutation of the calcium-sensing receptor gene.

Authors:  D E Cole; N Janicic; S R Salisbury; G N Hendy
Journal:  Am J Med Genet       Date:  1997-08-08

6.  HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome.

Authors:  J D Carpten; C M Robbins; A Villablanca; L Forsberg; S Presciuttini; J Bailey-Wilson; W F Simonds; E M Gillanders; A M Kennedy; J D Chen; S K Agarwal; R Sood; M P Jones; T Y Moses; C Haven; D Petillo; P D Leotlela; B Harding; D Cameron; A A Pannett; A Höög; H Heath; L A James-Newton; B Robinson; R J Zarbo; B M Cavaco; W Wassif; N D Perrier; I B Rosen; U Kristoffersson; P D Turnpenny; L-O Farnebo; G M Besser; C E Jackson; H Morreau; J M Trent; R V Thakker; S J Marx; B T Teh; C Larsson; M R Hobbs
Journal:  Nat Genet       Date:  2002-11-18       Impact factor: 38.330

7.  Rapid parathyroid hormone analysis during venous localization.

Authors:  Robert Udelsman; John E Aruny; Patricia I Donovan; Lori J Sokoll; Florie Santos; Richard Donabedian; Anthony C Venbrux
Journal:  Ann Surg       Date:  2003-05       Impact factor: 12.969

8.  Parathyroid autotransplantation in primary parathyroid hyperplasia.

Authors:  S A Wells; G J Ellis; J C Gunnells; A B Schneider; L M Sherwood
Journal:  N Engl J Med       Date:  1976-07-08       Impact factor: 91.245

9.  The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1 patient.

Authors:  N W Thompson
Journal:  J Intern Med       Date:  1995-09       Impact factor: 8.989

10.  Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer.

Authors:  W S Wassif; C F Moniz; E Friedman; S Wong; G Weber; M Nordenskjöld; T J Peters; C Larsson
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

View more
  14 in total

1.  Preoperative localizing studies for initial parathyroidectomy in MEN1 syndrome: is there any benefit?

Authors:  Naris Nilubol; Lee Weinstein; William F Simonds; Robert T Jensen; Giao Q Phan; Marybeth S Hughes; Steven K Libutti; Stephen Marx; Electron Kebebew
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

Review 2.  Hypercalcemia in children and adolescents.

Authors:  Steven A Lietman; Emily L Germain-Lee; Michael A Levine
Journal:  Curr Opin Pediatr       Date:  2010-08       Impact factor: 2.856

3.  CT-MIBI-SPECT image fusion predicts multiglandular disease in hyperparathyroidism.

Authors:  Gerd Wimmer; Christoph Profanter; Peter Kovacs; Michael Sieb; Michael Gabriel; Daniel Putzer; Reto Bale; Raimund Margreiter; Rupert Prommegger
Journal:  Langenbecks Arch Surg       Date:  2009-08-25       Impact factor: 3.445

4.  Outcomes after subtotal parathyroidectomy for primary hyperparathyroidism due to hyperplasia: significance of whole vs. partial gland remnant.

Authors:  Mohammad H Rajaei; Sarah C Oltmann; David F Schneider; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2014-09-23       Impact factor: 5.344

Review 5.  Hereditary hyperparathyroidism--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Maurizio Iacobone; Bruno Carnaille; F Fausto Palazzo; Menno Vriens
Journal:  Langenbecks Arch Surg       Date:  2015-10-08       Impact factor: 3.445

6.  Familial isolated hyperparathyroidism: role of intra operative parathormone assay.

Authors:  P V Pradeep; K Ramalingam
Journal:  Indian J Surg       Date:  2012-03-13       Impact factor: 0.656

7.  Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association?

Authors:  Enrico Erdas; Nicola Aste; Luca Pilloni; Angelo Nicolosi; Sergio Licheri; Antonello Cappai; Marco Mastinu; Filomena Cetani; Elena Pardi; Stefano Mariotti; Mariano Pomata
Journal:  BMC Cancer       Date:  2012-12-22       Impact factor: 4.430

Review 8.  Post-surgical follow-up of primary hyperparathyroidism associated with multiple endocrine neoplasia type 1.

Authors:  Flavia L Coutinho; Delmar M Lourenco; Rodrigo A Toledo; Fabio L M Montenegro; Sergio P A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 9.  Biochemical, bone and renal patterns in hyperparathyroidism associated with multiple endocrine neoplasia type 1.

Authors:  Delmar M Lourenço; Flavia L Coutinho; Rodrigo A Toledo; Tatiana Denck Gonçalves; Fabio L M Montenegro; Sergio P A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 10.  Primary hyperparathyroidism in multiple endocrine neoplasia type 1: when to perform surgery?

Authors:  Francesca Giusti; Francesco Tonelli; Maria Luisa Brandi
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.